Protagonist Therapeutics (PTGX) Gets a Buy from Truist Financial
Truist Financial analyst Srikripa Devarakonda reiterated a Buy rating on Protagonist Therapeutics (PTGX – Research Report) today. The company’s ...
Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX) and Roche Holding AG (OtherRHHVF)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Protagonist Therapeutics (PTGX – Research Report) and Roche ...
Why Is Protagonist Therapeutics Stock Trading Higher On Monday?
On Monday, Protagonist Therapeutics, Inc. PTGX announced topline results from ANTHEM-UC Phase 2b study of icotrokinra ...
How a skin drug trial could help Peninsula biotech pull off key merger
Alumis Inc.'s twice-a-day oral drug totally cleared the skin of telltale red, itchy patches in nearly 39% of 80 ...
JPMorgan Chase & Co. Issues Positive Forecast for Protagonist Therapeutics (NASDAQ:PTGX) Stock Price
Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) had its price target upped by analysts at JPMorgan Chase & Co. from ...
Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and Takeda Pharmaceutical Co Ltd (NYSE:TAK) released topline results for the ...
Protagonist Therapeutics (NASDAQ:PTGX) Earns Buy Rating from HC Wainwright
HC Wainwright restated their buy rating on shares of Protagonist Therapeutics (NASDAQ:PTGX – Free Report) in a research report released on Monday morning,Benzinga reports. They currently have a $54.00 ...
News Flash: 10 Analysts Think Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Earnings Are Under Threat
The latest analyst coverage could presage a bad day for Protagonist Therapeutics, Inc. (NASDAQ:PTGX), with the analysts making across-the-board cuts to their statutory estimates that might leave ...
Hosted on MSN21d
Protagonist Therapeutics' SWOT analysis: stock poised for growth amid clinical milestones
Protagonist Therapeutics, Inc. (NASDAQ:PTGX), a biopharmaceutical company with a market capitalization of $2.3 billion focused on developing peptide-based drugs, stands at a pivotal juncture in ...